Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael R. Cavanaugh
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 52
- Beta
- 1.80
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.22
Financials
Revenue
$0.00-100.0%Net Income
$-7.10MEBITDA
$-6.07MFree Cash Flow
$-5.34MEPS (diluted)
$-52.54Shares Outstanding (diluted)
135.2K+2380.7%Operating Expenses
$6.07MCash & Debt
$2.11MRevenue by Segment (annual)
$3.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-8.88M | $-7.84 |
| 2025 | $0.00 | $-5.66M | $-19.68 |
| 2024 | $1.18M | $-8.24M | $-176.80 |
| 2023 | $1.84M | $-10.10M | $-1768.00 |
| 2022 | $1.26M | $-8.49M | $-4133.60 |
| 2021 | $860.0K | $-3.64M | $-667.69 |
| 2020 | $420.0K | $-4.15M | $-761.09 |
Valuation
VBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+71.43%Social Signal Score
Mentions (5)
- Newsaccessnewswire.com·1d ago·Positive
…nment funding, FDA designations, human safety data and wholly owned U.S. manufacturing SAN ANTONIO, TX / ACCESS Newswire / October 5, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today outlined the perspectives of its new Board Chair, Thomas H. Jensen, on advancing Entolimod.
View source ↗ - Newsaccessnewswire.com·6d ago·Neutral
…ether the formulation delivers measurable amounts of Entolimod into the bloodstream SAN ANTONIO, TX / ACCESS Newswire / September 30, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and Shear Kershman Laboratories ("SKL") today announced the successful completion of formulation work under the companies' ongoing program to develop a novel oral mucosal formulation of Entolimod*, Valion's investigational biologic aimed at protecting cells from severe damage or death from radiation…
View source ↗ - Newsaccessnewswire.com·13d ago·Neutral
…advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced decisive changes to its executive leadership team and Board of Directors (the "Board"). These leadership transitions are intended to strengthen organizational alignment and support focused execution as Valion advances its Entolimod and oth…
View source ↗ - Newsaccessnewswire.com·53d ago·Negative
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement Formal review accepted July 22 • Ministry begins technical assessment • Regulatory requirements defined • Potential decision as early as Q4 2026 Near-Term Regulatory Catalyst Formal review underway: Ukraine's Ministry of Health accepted the Entolimod d
View source ↗ - Newsaccessnewswire.com·55d ago·Negative
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall Study drug delivered • IACUC approval secured • Safety study planned to start this week Near-Term Program Milestones Study readiness: Entolimod has been delivered to AFRRI, IACUC approval has been obtained, and study animals are being acclimated ahead of dosing.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-408.00 per share
Typical surprise +97.9% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-54.25 vs $-10200.00beat
- Thu, May 14$-2.23 vs $-85.00beat
- Tue, Mar 31$-0.82 vs $-85.00beat
- Sat, Nov 15$-0.01 vs $-102.00beat
- Fri, Nov 14$-2.19 vs $-102.00beat
- Fri, Mar 28$-2.65 vs $-119.00beat
Estimates and results for VBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VBIO officers and directors.
- Bought
- $2.1m
- Sold
- —
15 trades
0 trades
- Loconti Joseph E.bought
- Loconti Joseph E.bought
- Loconti Joseph E.bought
- Loconti Joseph E.bought
- Loconti Joseph E.bought
- Loconti Joseph E.bought
- Loconti Joseph E.bought
- Loconti Joseph E.bought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VBIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.